Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

CVS Caremark 4th-Quarter Profit Rose 2.6% Amid Continued Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 01:52pm CEST
   By Tess Stynes 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as the company reported revenue growth in its pharmacy-services and retail drugstore operations.

For the year, the company raised its forecast for per-share adjusted earnings from continuing operations by two cents and now expects $3.86 to $4.

CVS's retail pharmacy business gained customers last year in the wake of a contract dispute between rival Walgreen Co.'s (>> Walgreen Company) and pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) that has since been resolved.

A wave of major generic drugs introductions is having a mixed effect on the industry. Though the copycat drugs carry higher margins than branded products, they command lower prices, hurting sales revenue.

CVS Caremark reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-extinguishment losses, acquisition-related charges and other items, adjusted earnings from continuing operations were $1.14. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Revenue in the larger pharmacy-services business climbed 17% to $18.6 billion, reflecting new client starts, higher prices and growth of its Medicare Part D program. Pharmacy network claims processed rose 6.5%.

On the retail side, revenue increased 5.1% to $16.3 billion. Same-store sales were up 4% from a year earlier, as pharmacy same-store sales also improved by 4%. Same-store sales in the front end of the store grew 3.9%.

Shares closed Tuesday at $51.72 and were inactive premarket.

Write to Tess Stynes at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORP
05/27 CVS HEALTH : Dennison landmark Twin City Pharmacy to become CVS Pharmacy
05/25 CVS HEALTH : Standoff with armed robber at Media CVS ends peacefully
05/24 CVS HEALTH : Petition urges Laguna Beach planners to deny CVS' application
05/23 CVS HEALTH : Attorney General Brnovich, Rep. Carter Join CVS Health to Announce ..
05/19 CVS HEALTH CORP (NYSE : CVS) Omnicare Unit Agrees To Pay Up To $8 Million For Fa..
05/19 CVS HEALTH : Removing Chemicals of Consumer Concern
05/18 CVS HEALTH : American Lung Association's LUNG FORCE Encourages Americans to Take..
05/17 Wells Fargo, CVS tumble; Target and Red Robin Gourmet gain
05/17DJCVS HEALTH : Why Your Pharmacy May Be Texting You -- WSJ
05/16 CVS HEALTH CORP (NYSE : CVS) Unveils Long Live Skin Campaign As Part Of Skin Can..
More news
Sector news : Drug Retailers - NEC
05/15 SHANGHAI PHARMACEUTICALS : Advent, Shanghai Pharma have not approached Stada - s..
05/02 CVS HEALTH : profit beats as pharmacy margins rise
04/26 PayPal's profit, revenue beat on higher processing volumes
04/26DJANTHEM : Says ACA Payment Loss Could Cause 20% Premium Hike -- Update
04/26DJExpress Scripts Faces Tough Test -- WSJ
More sector news : Drug Retailers - NEC
News from SeekingAlpha
05/26 Oil Service Firms Investments Key To Halting Venezuela's Post-Maduro Producti..
05/26 Putting My Core Conviction Stocks To The Test
05/24 Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q1 2017 Upda..
05/24 What Do You Do When Social Security Falls Short Of Your Needs?
05/22 My 83 Stock Portfolio Requirements And Listing Of Do Not Sell, Core And Specu..
Advertisement
Financials ($)
Sales 2017 184 339 M
EBIT 2017 10 170 M
Net income 2017 5 384 M
Debt 2017 24 592 M
Yield 2017 2,53%
P/E ratio 2017 14,95
P/E ratio 2018 13,16
EV / Sales 2017 0,56x
EV / Sales 2018 0,53x
Capitalization 78 080 M
More Financials
Chart CVS HEALTH CORP
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 86,8 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP-2.88%78 080
WALGREENS BOOTS ALLIAN..-1.82%87 827
EXPRESS SCRIPTS HOLDIN..-13.13%35 875
MCKESSON CORPORATION14.77%33 997
CARDINAL HEALTH INC1.57%23 091
AMERISOURCEBERGEN CORP..16.38%19 870
More Results